Prophylaxis extension for venous thromboembolism after major abdominal and pelvic surgery for cancer (prevent): Quality improvement transitioned into a cohort study

被引:1
|
作者
McKechnie, Tyler [1 ]
Tywonek, Kasia [1 ]
Simunovic, Marko [1 ,2 ]
Serrano, Pablo E. [1 ,2 ,3 ]
机构
[1] McMaster Univ, Dept Surg, Div Gen Surg, Hamilton, ON, Canada
[2] Juravinski Hosp, Dept Surg, Div Gen Surg, Hamilton, ON, Canada
[3] McMaster Univ, Dept Surg, Div Hepatobiliary Surg, 711 Concess St,Rm B3-161, Hamilton, ON L8V 1C3, Canada
关键词
AMERICAN SOCIETY; TRENDS;
D O I
10.1016/j.surg.2021.12.037
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Extended venous thromboembolism prophylaxis after abdominopelvic cancer surgery has not been widely adopted. We compared outcomes of patients pre-and postimplementation of extended venous thromboembolism prophylaxis with low molecular weight heparin. Methods: Prospectively collected data from a quality initiative project aimed at prescribing extended venous thromboembolism prophylaxis after abdominopelvic cancer surgery was compared with previously published data from a prospective cohort without extended venous thromboembolism prophylaxis. The primary outcome was 6-month postoperative symptomatic venous thromboembolism incidence. Secondary outcomes: differences in 1-and 3-month venous thromboembolism incidence and factors associated with venous thromboembolism using Cox-proportional hazard models. Cumulative incidence of venous thromboembolism was estimated using Kaplan-Meier methods and expressed as proportions with 95% confidence interval. Results: There were 241 patients in the venous thromboembolism-prophylaxis cohort and 284 patients in the no venous thromboembolism prophylaxis cohort. Patients in the venous thromboembolismprophylaxis cohort were more likely to be female (69% vs 60%, P = .018), have metastatic disease (49% vs 29%, P < .001), have longer operative times (236 min vs 197 min, P < .001), and to receive neoadjuvant chemotherapy (27% vs 23%, P = .006). Respectively, the 1-(0.5% [95% confidence interval, 0.1-2.5] vs 0.4% [95% confidence interval, 0.1-2.5]), 3-(2.6% [95% confidence interval, 1.2-5.6] vs 2.5% [95% confidence interval, 1.2-5.2]), and 6-month (7.5% [95% confidence interval, 4.8-11.5] vs 7.2% [95% confidence interval, 4.7-11.0]) venous thromboembolism incidence were similar. By multivariable analysis, history of venous thromboembolism (hazard ratio 3.52; 95% confidence interval, 1.03-12.05; P = .045) and longer duration of hospital stay (hazard ratio 1.07; 95% confidence interval, 1.01-1.12; P = .016) demonstrated increased risk of venous thromboembolism. Conclusion: This study failed to demonstrate a decreased 1-, 3-, and 6-month postoperative venous thromboembolism incidence after the implementation of extended venous thromboembolism prophylaxis. (c) 2022 Elsevier Inc. All rights reserved.
引用
收藏
页码:234 / 240
页数:7
相关论文
共 50 条
  • [1] Efficacy and safety of extended pharmacological venous thromboembolism (VTE) prophylaxis after major abdominal and pelvic surgery: an international, prospective cohort study
    Sgro, A.
    BRITISH JOURNAL OF SURGERY, 2023, 110 : III24 - III24
  • [2] Quality improvement study of extended venous thromboembolism prophylaxis compliance after colorectal cancer surgery
    Pouzi, A.
    Karim, S.
    Qureshi, M. Saeed
    Malik, A.
    BRITISH JOURNAL OF SURGERY, 2018, 105 : 106 - 106
  • [3] Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study
    Kakkar, V. V.
    Balibrea, J. L.
    Martinez-Gonzalez, J.
    Prandoni, Paolo
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (06) : 1223 - 1229
  • [4] EXTENDED VENOUS THROMBOEMBOLISM PROPHYLAXIS WITH RIVAROXABAN DOES NOT INCREASE BLEEDING COMPLICATIONS AFTER MAJOR ABDOMINAL AND PELVIC SURGERY.
    Kebkalo, A.
    Tyselskyi, V.
    Reiti, A.
    Wong, D.
    Poylin, V.
    DISEASES OF THE COLON & RECTUM, 2020, 63 (06) : E232 - E232
  • [5] 28 Days of Extended Pharmacological Venous Thromboembolism in major abdominal and pelvic cancer surgery
    Al-Sheikh, M.
    Panesar, K.
    Loganathan, A.
    BRITISH JOURNAL OF SURGERY, 2016, 103 : 122 - 123
  • [6] Implementation of extended prolonged venous thromboembolism prophylaxis with rivaroxaban after major abdominal and pelvic surgery - overview of safety and early outcomes
    Tyselskyi, Volodymyr V.
    Wong, Daniel
    Tryliskyy, Yegor
    Poylin, Vitaliy Y.
    Kebkalo, Andrey B.
    POLISH JOURNAL OF SURGERY, 2020, 92 (06) : 22 - 26
  • [7] Combined pharmacologic and mechanical prophylaxis for the prevention of venous thromboembolism after major abdominal surgery: Results of the APOLLO study
    Caprini, J
    Bauer, K
    Comp, P
    Gent, M
    Muntz, J
    Turpie, A
    Beart, R
    DISEASES OF THE COLON & RECTUM, 2006, 49 (05) : 744 - 745
  • [8] Thromboprophylaxis does not prevent venous thromboembolism after major surgery
    Attia, Adel
    Ali, Hitham
    Al Amory, Mohammed
    Othman, Hosam
    EGYPTIAN JOURNAL OF CHEST DISEASES AND TUBERCULOSIS, 2015, 64 (01): : 249 - 254
  • [9] Effectiveness of Standardized Venous Thromboembolism Prophylaxis Order Sets in Patients Undergoing Abdominal or Pelvic Surgery for Cancer
    Mandernach, Molly Weidner
    Lottenberg, Richard
    Johns, Thomas
    Speed, Elaine
    Findlay, Russell L.
    Hou, Wei
    Rajasekhar, Anita
    BLOOD, 2012, 120 (21)
  • [10] Prophylaxis against venous thromboembolism after surgery for cancer
    Moulias, S
    Bouchon, JP
    Meaume, S
    NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (03): : 220 - 220